West Virginia Code § 16-51-2

Legislative findings
Open in Lexace · Ask the AI about this section
(a) The Legislature finds and declares that:
(1) The process of approval for investigational drugs, biological products and devices in the
United States protects future patients from premature, ineffective and unsafe medications
and treatments over the long run, but the process often takes many years;
(2) Patients who have a terminal illness do not have the luxury of waiting until an
investigational drug, biological product or device receives final approval from the United
States Food and Drug Administration; u
(3) Patients who have a terminal illness have a fundamental right to attempt to pursue the
preservation of their own lives by accessing available investigational drugs, biological
products and devices; a
(4) The use of available investigational drugs, biololgical products and devices is a decision
that should be made by the patient with a terminal illness in consultation with the patient's
health care provider and the patient's health care team, if applicable; and
(5) The decision to use an investigational drug, biological product or device should be made
with full awareness of the potential risks, benefits and consequences to the patient and the
patient's family.
(b) It is the intent of the Legislature to allow for terminally ill patients to use potentially life-
saving or pain-relieving investigational drugs, biological products and devices.

‹ Prev All West Virginia sections Next ›


Lexace provides legal information, not legal advice, and no attorney–client relationship is created. Statute text is provided for general information and may not reflect the most recent amendments; verify against the official state code.